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S232 Poster Session I0%-43%) and 10% (95%CI, 0%-23%) for MRD and CB, respec-
tively (p5 0.6)
Conclusion:The use of allogeneic HSCTwith RIC provides favor-
able disease outcomes in older AML patients in CR1. CB should be
considered as an alternative donor source in patients with no MRD
donor available.199
SYNERGISTIC CYTOTOXICITY OF CLOFARABINE, FLUDARABINE AND BU-
SULFAN: RELEVANCE TO MYELOABLATIVE THERAPY
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Clofarabine (Clo) and Fludarabine (Flu) are purine nucleoside an-
alogues (NA) with antileukemia activity. Their synergistic cytotoxic-
ity in the absence or presence of DNA alkylating drug Busulfan (Bu)
has not been reported. To determine the efficacy and synergism of
these three drugs in Bu-resistant AML cell line (KBM3/Bu2506),
various combinations were analyzed for their cytotoxicity. Clo, Flu
and Bu have IC50 values of 0.03 mM, 1.22 mM and 126 mM, respec-
tively. Combination of 0.01 mM Clo and 0.2 mM Flu resulted in
84% cell survival after 4 d; addition of 40 mMBu to this combination
decreased cell survival to 59% suggesting synergism. Cell cycle anal-
ysis after 2-day exposure of cells to either 0.015 mM Clo or 0.6 mM
Flu showed 6% cells in sub-G1. When combined at the same con-
centrations, 20% cells were in sub-G1 and 5% were TUNEL-posi-
tive. Addition of 80 mM Bu to this combination increased sub-G1
and TUNEL-positive cells to 35% and 15%, respectively. These re-
sults suggest synergistic efficacy of Clo and Flu which further im-
proves with addition of Bu. Immunoblot analysis of cells exposed
to 0.015 mM Clo + 0.6 mM Flu resulted in significant cleavage of
PARP1 and increased g-H2AX compared with exposure to either
NA alone; addition of 80 mM Bu increased the effects two-fold.
These results suggest drug-mediated induction of DNA damage re-
sponse and apoptosis. Inhibition of ribonucleotide reductase (RNR)
with 100 mMhydroxyurea (HU) was also synergistic with Clo or Flu.
The effects of [Clo + Flu], [Clo +HU] and [Flu +HU] were reversed
by 100 mM cytidine. These data support self-potentiation of [Clo + -
Flu] combination as a possible mechanism of their synergistic cyto-
toxicity where both NA inhibit RNR, decrease deoxynucleotide
synthesis and make more deoxycytidine kinase available to phos-
phorylate and activate Clo and Flu. This mechanism may result in
enhanced incorporation of Clo and Flu during DNA synthesis.
[Clo + Flu] combination also resulted in more significant methyla-
tion of histone H3 suggesting increased chromatin remodeling
which possibly exposed more DNA to Bu-mediated cross-linking
and explains the observed synergism of [Clo + Flu + Bu]. This model
is consistent with a dramatic increase in the level of g-H2AX, an in-
dicator of DNA damage, when Bu was added to [Clo + Flu] combi-
nation. Overall, our results suggest that addition of [Clo + Flu]
might synergistically improve the cytoreductive efficacy of Bu-based
pre-transplant regimen in myeloid leukemia patients.200
EFFECTS OF CHANGES IN CONDITIONING REGIMEN AND SUPPORTIVE
CARE ON OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
(AML) AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
Abello, V., Rosales, C., Pedraza, E., Linares, A., Esguerra,H., Rosales,M.,
Figueroa, J. Clınica de Marly, Bogota, Colombia
As in all centers around de world, transplant strategies have change
in our center over the time.Here we report the results of a single cen-
ter, retrospective analysis of outcomes in patients with AML treated
with high dose therapy and allo-SCT, from 1994 to 2009, comparing
patients treated before and after 2005whenwe changed conditioning
regimen for AML to Fludarabine-Busulfan and implemented sup-
portive measures as Levofloxacine as prophylaxis, CMV pre-emptive
strategy, and EICH prophylaxis with Micofenolate (MMF).
Since 1994, 59 LMA patients have been treated, 57 received pe-
ripheral blood HLA identical related grafts and 2 patients receivedUR cord blood transplants. As conditioning, 3 patients received
RIC and 56 full intensity conditioning (BuCy 25 – BuFlu 23 – other
8). Only 3 (5%) had high risk cytogenetics at diagnosis but 40%were
considered of high risk at transplantation (44% for BuCy and 39%
for BuFlu). Table 1. Describes patient characteristics and outcomes
for all patients and BuCy vs BuFlu groups. Of note BuCy and BuFlu
groups are very similar except for CMV positivity 56 vs 78% and
time from diagnosis to transplant 24 months (2.3-167) vs 14.5
(2.13-33).
BuFlu patients received routine Levofloxacine prophylaxis (78%
vs 0% BuCy group), GVHD mainly with Cs-MMF (69% vs BuCy
group 28%) and were treated for CMV in a preemptive strategy.
As shown in table toxicity related to the procedure was greatly re-
duced with BuFlu strategy, having a shorter hospital stay, less fever,
diarrhea, requiring less antibiotics and transfusion support. There
were no toxic deads in BuFlu group.
For BuCy group, at a median follow-up of 12.8 months (range 0.5-
118.), 9 patients are alive in CR (36%), 4 were lost for follow-up
(16%) and 12 died (48%). 4 patients (16%) died before day 100 of
transplant related causes. Main cause of death was relapse in 7
(58.3%).
For BuFlu group, at a median follow-up of 7 months (range 1-40),
13 (56.5%) are alive in CR, 1 is alive in relapse (4.3%) and 9 died
(39.1%). No patient died before day 100. Relapse has been the
main cause of dead so far, 4 (33.3%); followed by pulmonary compli-
cations, 3 (25%) and EICH related complications 2 (16.7%).
This retrospective analysis suggest benefit of Bu-Flu and newer
supportive strategies in early toxicity related to HLA familial allo-
SCT over BuCy. Longer follow-up and greater numbers of patients
are needed to draw conclusions about its significance in long-term
survival.
Patient characteristics and outcomes
All (N 59) BuCy (N. 25) Bu-Flu (N. 23)Gender (M/F) 32/27 12/13 14/11
Age 34 (6-63) 34.9 (6-55) 33.8 (10-61)
# Previus cycles 4.67 (1-16) 4.5 (1-16) 4.7 (1-9)
CD341x10-6/kg 3.3 (0.3-11.1) 2.9 (1.1-8) 2.9 (0.8-11)
Hospital stay 32.1 (21-80) 34.7 (22-54) 27.3 (22-40)
% weigth loss 5 (-3.4 – 13.6) 6 (0-12.9) 3.7 (-3.4-12.1)
Neutrophyls graft 13 (6-43) 14 (9-43) 11 (6-14)
Fever (days) 4.1 (0-22) 4.8 (1-20) 1.9 (0-5)
Diarrhea (days) 3.9 (0-21) 5 (0-15) 2.9 (0-21)
TPN (days-% patients) 6.2 (0-25)-61% 8.3 (0-21)-72% 3.1 (0-10)-48%
Antibiotic days 32.4 (0-127) 42.56 (12-127) 17 (0-49)
RBC transfusion 1.8 (0-28) 1.92 (0-14) 0.6 (0-5)
PLT transfusion 4.9 (0-35) 6.5 (1-27) 1.4 (0-18)
Mortality\100 days 6.7% 16% 0%201
UNRELATED DONOR REDUCED-INTENSITY STEM CELL TRANSPLANTA-
TION IS A PROMISING TREATMENT OPTION FOR ELDERLY PATIENTS
WITH BLASTIC PLASMOCYTOID DENDRITIC CELL NEOPLASM (BPDC)
Dietrich, S.1, Hegenbart, U.1, Schmitt, T.1, Martens, U.2, Ho, A.D.1,
Dreger, P.1 1University of Heidelberg, Heidelberg, Germany; 2SLK-Kli-
niken, Heilbronn, Germany
Blastic plasmacytoid dendritic cell neoplasm (BPDC), formerly
known as blastic NK cell lymphoma, is a rare hematopoietic malignancy
preferentially involving skin, bone marrow and lymph nodes. The
overall prognosis of BPDC is dismal. Most patients show an initial
response to acute leukemia-like chemotherapy, but relapses with
subsequent drug resistance occur in virtually all patients resulting
in a median overall survival of only 9-13 months. However, anec-
dotal long-term remissions have been reported in young patients
who received early myeloablative allogeneic stem cell transplanta-
tion (alloSCT). As the median age at diagnosis is above 60 years,
most patients at risk will not be eligible for myeloablative alloSCT.
Here we present our experience with reduced-intensity conditioning
(RIC) alloSCT from unrelated donors in elderly patients with
BPDC.
